URGN Stock: Price, Earnings History and SEC Filings
UroGen Pharma Ltd. (URGN) last traded at $32.72, down 2.27% on the latest session and down 19.5% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-0.28 against an analyst estimate of $-0.38, a beat of 26.3%.
$32.72 -2.27%
1 month-19.47%
52-week high$50.81
52-week low$16.50
Volume1.17M
ExchangeNasdaqGM
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
URGN earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 5, 2026 | $-0.28 | $-0.38 | +26.32% |
| Mar 2026 | May 6, 2026 | $-0.47 | $-0.56 | +16.07% |
| Dec 2025 | Mar 2, 2026 | $-0.54 | $-0.66 | +18.18% |
| Sep 2025 | Nov 6, 2025 | $-0.69 | $-0.72 | +4.17% |
URGN beat the analyst EPS estimate in 4 of its last 4 reported quarters. Source: Nasdaq.
Latest SEC filings for URGN
SEC filing data is not available right now. You can search for URGN on SEC EDGAR.
URGN news
- Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 ReleaseOct 29, 2026 · finance.yahoo.com
- UroGen’s Final Results from Olympus Five-Year Follow-Up Study Reinforces Durable Response with JELMYTO in Patients with Low-Grade Upper Tract Urothelial CancerOct 28, 2026 · finance.yahoo.com
- UroGen Pharma to Report Third Quarter 2026 Financial Results on Wednesday, November 4th, 2026Oct 27, 2026 · finance.yahoo.com
- Why UroGen Pharma (URGN) Is Getting Fresh Attention NowOct 20, 2026 · finance.yahoo.com
- UroGen Announces FDA Acceptance of the New Drug Application for UGN-103, an Investigational Treatment for Adults with Recurrent LG-IR-NMIBCOct 19, 2026 · finance.yahoo.com
About UroGen Pharma Ltd.
UroGen Pharma Ltd. (URGN) is a US-listed public company on Nasdaq.